Solomon et al. (74) |
174 |
Prospective, cohort study compared with historical controls |
No |
A single positive blood culture |
Taurolidine 1.35%/citrate 4%/heparin 500 U/ml |
a) Heparin 5000 U/ml |
a1) Bloodstream infection |
a1) 1.33 versus 3.25 |
a1) 0.001 |
Cost |
b) Taurolidine 1.35%/Citrate 4% |
a2) First use of thrombolytic |
a2) RR 1.4 (0.5–3.9) |
a2) 0.5 |
b1) Blood stream infection |
b1) 1.33 versus 1.22 |
b1) 0.001 |
b2) First use of thrombolytic |
b2) RR0.2 (0.06 to 0.5) |
b2) 0.001 |
Winnicki et al. (75) |
106 |
Multicenter, randomized, controlled trial |
No |
A positive bacterial blood culture drawn from the dialysis catheter in a symptomatic patient with fever or chills associated with dialysis and no apparent other source of infection |
Taurolidine 1.35%/citrate 4%/heparin 500 U/ml twice a wk with taurolidine 1.35%/citrate 4%/urokinase 25,000 U once a wk |
Citrate 4% |
a) Bloodstream infection |
a) 0.67 versus 2.7 |
0.003 |
Cost |
b) Catheter dysfunction |
b) 18.7 versus 44.3 |
0.001 |
Al-Ali et al. (76) |
164 |
Multicenter, single- blinded, randomized, controlled trial |
No |
Same organism obtained from blood aspirated through the catheter hub and from blood sample obtained from peripheral vein with no other identifiable cause of infection |
Taurolidine 1.35%/citrate 4%/heparin 500 U/ml twice a wk with taurolidine 1.35%/citrate 4%/urokinase 25,000 U once a wk |
Taurolidine 1.35%/citrate 4%/heparin 500 U/ml three times a wk |
a) Catheter removal for bloodstream infection |
a) 0 versus 3 |
0.08 |
Cost |
b) Catheter removal for dysfunction |
b) 1 versus 4 |
0.17 |
c) Need for tissue plasminogen activator use |
c) 5 versus 12 |
0.61 |